CATALYTICALLY ACTIVE CLOSTRIDIUM BOTULINUM NEUROTOXIN E Rakhi Agarwal and Subramanyam Swaminathan Biology Department, Brookhaven National Laboratory, Upton, New York 11973 USA Running title: Crystal structure of BoNT E -SNAP-25 peptide complex Corresponding author: S. Swaminathan, Biology Department, Brookhaven National Laboratory, Upton, NY 11973, USA. Phone-1(631)344-3187, Fax: 1(631)344-3407...

The unique ability of a family of botulinum neurotoxins to block neuroexocytosis specifically-by selective interaction with peripheral cholinergic nerve endings, endocytotic uptake, translocation to the cytosol, and enzymic cleavage of essential proteins-underlies their increasing therapeutic applications. Although clinical use of type A is most widespread due to its prolonged inactivation of t...

AIM It is known that botulinum neurotoxin type A (BoNTA) improves some kinds of cancer (e.g. prostate) and that synaptic vesicle glycoprotein 2 (SV2) is the molecular target of this neurotoxin. Besides having potential therapeutic value, this glycoprotein has recently been proposed as a molecular marker for several types of cancer. Although the mechanisms of cancer development and the improveme...

BACKGROUND Botulinum neurotoxin (BoNT) complexes consist of neurotoxin and neurotoxin-associated proteins. Hemagglutinin-33 (HA-33) is a member of BoNT type A (BoNT/A) complex. Considering the protective role of HA-33 in preservation of BoNT/A in gastrointestinal harsh conditions and also its adjuvant role, recombinant production of this protein is favorable. Thus in this study, HA-33 was expre...

Even though conventional botulinum neurotoxin (BoNT) products have shown successful treatment results in patients with benign blepharospasm (BEB), the main, potential long-term side effect of BoNT use is the development of immunologic resistance due to the production of neutralizing antibody to the neurotoxin after repeated injections. Xeomin(®) (incobotulinumtoxinA), a unique botulinum neuroto...

This article reviews the current and most neurologic uses of botulinum neurotoxin type A (BoNT-A), beginning with relevant historical data, neurochemical mechanism at the neuromuscular junction. Current commercial preparations of BoNT-A are reviewed, as are immunologic issues relating to secondary failure of BoNT-A therapy. Clinical uses are summarized with an emphasis on controlled clinical tr...

This paper reviews the current and most neurological (central nervous system, CNS) uses of the botulinum neurotoxin type A. The effect of these toxins at neuromuscular junction lends themselves to neurological diseases of muscle overactivity, particularly abnormalities of muscle control. There are seven serotypes of the toxin, each with a specific activity at the molecular level. Currently, ser...

introduction: submucoperichondrial injection of botulinum neurotoxin a (bta) in the nasal septum is a promising therapeutic option in the treatment of persistent allergic rhinitis (ar) and non-allergic rhinitis, and is safer and more effective than intraturbinate injection in reducing clinical symptoms.   materials and methods: forty patients diagnosed with persistent ar or non-allergic rhiniti...